Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis.

Huy Gia VuongThu Quynh NguyenHoang Cong NguyenPhuoc Truong NguyenAn Thi Nhat HoLewis Hassell

Published in: Targeted oncology (2021)

Our study highlighted and confirmed the efficacy of crizotinib in patients with NSCLC with ROS1 or MET genetic alterations. Crizotinib had remarkable effects on advanced NSCLC with ROS1 fusion, as previously reported. However, the role of this targeted therapy in MET-altered NSCLC remains investigational.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
tyrosine kinase
cell death
reactive oxygen species
dna damage
small cell lung cancer
clinical trial
gene expression
oxidative stress
phase ii